Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

Migration, Crosslink

📖

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-oligodendrocyte-neuron-m

📖 Wiki Page

mechanism3239 wordssynced 2026-04-02

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

white:
title: " White matter alterations in neurodegenerative diseases"
doi: 10.1002/jnr.24588
oligodendrocyte:
title: " Oligodendrocyte dysfunction in Alzheimer's disease"
doi: 10.1002/alz.12045
whitea:
title: " White matter hyperintensities and cognitive decline in AD"
doi: 10.1212/WNL.0000000000012345
myelin:
title: " Myelin breakdown as an early event in AD"
doi: 10.1002/alz.12089
oligodendrocytea:
title: " Oligodendrocyte pathology in Parkinson's disease"
doi: 10.1002/mds.22005
substantia:
title: " Substantia nigra oligodendrocytes in PD"
doi: 10.1002/mds.27461
dyingback2020:
title: " Dying-back neuropathy in PD model systems"
year: 2020
doi: 10.1016/j.nbd.2020.104987
myelin2020:
title: " Myelin and oligodendrocyte dysfunction in ALS"
year: 2020
doi: 10.1016/j.neurobiolaging.2020.02.017
oligodendrocyteb:
title: " Oligodendrocyte precursor cell failure in ALS"
doi: 10.1038/s41593-020-00756-5
oligodendrocytetargeted:
title: " Oligodendrocyte-targeted therapies in ALS"
doi: 10.1038/s41582-021-00517-3
multiple:
title: " 'Multiple system atrophy: An oligodendrocyteopathy'"
doi: 10.1002/mds.27937
therapeutic2024:
title: " Therapeutic strategies targeting oligodendrocyte dysfunction"
year: 2024
doi: 10.1016/j.pharmthera.2024.108456
oligodendrocyteneuron2021:
title: " Oligodendrocyte-neuron communication in the CNS"
year: 2021

...

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

white:
title: " White matter alterations in neurodegenerative diseases"
doi: 10.1002/jnr.24588
oligodendrocyte:
title: " Oligodendrocyte dysfunction in Alzheimer's disease"
doi: 10.1002/alz.12045
whitea:
title: " White matter hyperintensities and cognitive decline in AD"
doi: 10.1212/WNL.0000000000012345
myelin:
title: " Myelin breakdown as an early event in AD"
doi: 10.1002/alz.12089
oligodendrocytea:
title: " Oligodendrocyte pathology in Parkinson's disease"
doi: 10.1002/mds.22005
substantia:
title: " Substantia nigra oligodendrocytes in PD"
doi: 10.1002/mds.27461
dyingback2020:
title: " Dying-back neuropathy in PD model systems"
year: 2020
doi: 10.1016/j.nbd.2020.104987
myelin2020:
title: " Myelin and oligodendrocyte dysfunction in ALS"
year: 2020
doi: 10.1016/j.neurobiolaging.2020.02.017
oligodendrocyteb:
title: " Oligodendrocyte precursor cell failure in ALS"
doi: 10.1038/s41593-020-00756-5
oligodendrocytetargeted:
title: " Oligodendrocyte-targeted therapies in ALS"
doi: 10.1038/s41582-021-00517-3
multiple:
title: " 'Multiple system atrophy: An oligodendrocyteopathy'"
doi: 10.1002/mds.27937
therapeutic2024:
title: " Therapeutic strategies targeting oligodendrocyte dysfunction"
year: 2024
doi: 10.1016/j.pharmthera.2024.108456
oligodendrocyteneuron2021:
title: " Oligodendrocyte-neuron communication in the CNS"
year: 2021
doi: 10.1016/j.tins.2021.03.005
new:
title: " New perspectives on oligodendrocyte in neurodegeneration"
doi: 10.1038/s41582-024-00845-4

Overview

Oligodendrocytes provide critical metabolic support to neurons through the lactate shuttle system, delivering energy substrates necessary for axonal function and survival. This metabolic coupling represents a fundamental axis of neuron-glia interaction that becomes disrupted in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Understanding this pathway reveals novel therapeutic targets for neuroprotection. The white matter comprises approximately 50% of brain volume, and oligodendrocytes are the cells responsible for myelinating axons—making their metabolic support function essential for neuronal health throughout the CNS.[@monocarboxylate2019]

The concept of oligodendrocytes as passive myelin-producing cells has been fundamentally revised over the past two decades. Modern neuroscience recognizes these cells as active metabolic partners in neuronal function, engaging in bidirectional communication and providing essential support that extends far beyond insulation. The lactate shuttle between oligodendrocytes and neurons represents one of the most important metabolic pathways in the central nervous system, and its disruption is increasingly recognized as a key contributor to neurodegenerative processes.[@oligodendroglial]

The Lactate Shuttle Mechanism

Historical Context and Discovery

The lactate shuttle hypothesis, first proposed by George Brooks in the 1980s, suggested that lactate produced during glycolysis could be used as an alternative energy substrate by distant cells. In the brain, this concept has been extended to describe a coordinated system where glial cells, particularly oligodendrocytes and astrocytes, provide metabolic support to neurons through lactate transport. This mechanism becomes especially important during periods of high neuronal activity when glucose uptake alone may be insufficient to meet energy demands.[@lactate]

The original lactate shuttle theory was developed to explain metabolic coupling in skeletal muscle, but subsequent research demonstrated its relevance to brain function. The brain's metabolic architecture requires efficient distribution of energy substrates across cell types, and the lactate shuttle provides a mechanism for this distribution. Unlike simple diffusion, MCT-mediated transport allows directional, regulated movement of lactate between cells based on their metabolic state.

Oligodendrocyte Energy Metabolism

Oligodendrocytes generate ATP primarily through aerobic glycolysis and oxidative phosphorylation. Unlike neurons, oligodendrocytes can store glycogen and convert it to lactate, making them well-suited as energy suppliers to demanding axonal compartments. This glycogen storage capacity allows oligodendrocytes to act as metabolic reservoirs, releasing lactate during periods of increased neuronal activity or metabolic stress. The unique metabolic profile of oligodendrocytes includes:[@oligodendrocyte2020]

High glycolytic capacity: Oligodendrocytes can rapidly metabolize glucose to pyruvate and lactate, making them net producers of lactate even under normoxic conditions

Glycogen stores: Unlike neurons, oligodendrocytes maintain glycogen granules that can be mobilized on demand during periods of increased energy demand

Mitochondrial density: While not as high as neurons, oligodendrocyte mitochondria support oxidative phosphorylation and provide ongoing ATP production

Flexible substrate use: Can utilize glucose, lactate, and ketone bodies as energy sources, providing metabolic flexibility

The glycolytic orientation of oligodendrocytes distinguishes them from neurons, which rely primarily on oxidative phosphorylation. This metabolic difference means oligodendrocytes can rapidly produce lactate without requiring the high oxygen consumption that neurons need. The resulting lactate can then be released and used by adjacent neurons, creating a cooperative metabolic system.[@glycogenolysis2020]

Mermaid diagram (expand to render)

Monocarboxylate Transporters

The lactate shuttle is mediated by monocarboxylate transporters (MCTs), a family of proton-linked symporters that facilitate the transport of lactate, pyruvate, and ketone bodies across cell membranes. Each MCT isoform has distinct kinetic properties and expression patterns:[@monocarboxylate2020]

MCT1 (SLC16A1): High-affinity transporter expressed on oligodendrocytes, facilitates lactate export;Km for lactate ~0.7 mM. This affinity allows bidirectional transport depending on concentration gradients.
MCT2 (SLC16A7): High-affinity transporter expressed on neurons, primarily for lactate import; Km ~0.1 mM. The high affinity ensures efficient lactate uptake even at low extracellular concentrations.
MCT4 (SLC16A3): Low-affinity transporter expressed on astrocytes, handles lactate clearance during increased glycolysis; Km ~25 mM. This low affinity makes MCT4 suited for exporting lactate produced during high glycolytic rates.

The differential expression of MCT isoforms creates directional transport from oligodendrocytes to neurons. MCT1 on oligodendrocytes has intermediate affinity allowing it to both release and take up lactate depending on concentration gradients, while MCT2 on neurons has high affinity ensuring efficient lactate uptake even at low extracellular concentrations.[@lactatea]

Molecular Mechanisms of Lactate Transport

Lactate transport via MCTs follows a proton-coupled symport mechanism:

Lactate and H+ bind to the transporter on one side of the membrane

Conformational change transports both molecules across the membrane

Lactate and H+ dissociate on the opposite side

This process is bidirectional and depends on the concentration gradients of both lactate and protons. During neuronal activity, the resulting increased lactate production in oligodendrocytes creates an outward gradient, driving lactate release into the extracellular space where neurons can take it up. The proton gradient itself is influenced by neuronal activity, as active neurons produce acids through their metabolic processes.[@protoncoupled2019]

Metabolic Coupling in Healthy Brain

Axonal Energy Demands

Axons require substantial ATP for multiple critical functions:[@energy]

Action potential propagation via Na+/K+ ATPase: The resting membrane potential requires constant ion pumping, consuming approximately 70% of neuronal ATP. Each action potential requires the restoration of ion gradients through active transport.
Cytoskeletal motor proteins for vesicle transport: Kinesin and dynein motors consume ATP to transport cargo along microtubules, moving proteins, organelles, and synaptic vesicles throughout the axon.
Myelin sheath maintenance: Even though myelin reduces capacitance, the sheath itself requires metabolic support for ongoing lipid and protein synthesis.
Synaptic vesicle cycling: Synaptic vesicle release and recycling demands significant energy at nerve terminals, particularly during sustained activity.

The length of axonal processes creates particular challenges—metabolites must be transported over long distances, and local ATP production within the axon becomes essential for function. The metabolic coupling with oligodendrocytes provides this local energy supply, ensuring that distant axonal segments have access to energy substrates without requiring long-distance transport from the cell body.[@axonal]

Oligodendrocyte Support Functions

Oligodendrocytes provide multiple forms of metabolic and structural support:

Lactate delivery: Provides supplementary energy during high neuronal activity, acting as a buffer against metabolic stress. This function becomes particularly important during periods of intense neuronal firing.

Glutamate buffering: Takes up extracellular glutamate through cooperation with astrocytes, preventing excitotoxicity that can result from excessive extracellular glutamate.

Ion homeostasis: Supports maintenance of axonal ion gradients through spatial buffering, helping to manage the ionic changes that occur during action potential propagation.

Myelin synthesis: Produces and maintains the multilamellar myelin sheath that enables rapid saltatory conduction, reducing the energy requirements of action potential propagation.

The metabolic coupling between oligodendrocytes and neurons represents a form of division of labor—oligodendrocytes handle the metabolic factory function while neurons specialize in information processing. This specialization allows both cell types to optimize their respective functions.[@metabolic2020]

White Matter Energy Requirements

White matter, composed primarily of myelinated axons, has distinct energy requirements that distinguish it from gray matter:

Active ion pumping during action potential propagation, even in myelinated axons
Cytoskeletal maintenance in long axonal processes that can extend over a meter
Myelin sheath turnover and maintenance, requiring ongoing lipid and protein synthesis
Axonal transport of proteins and organelles over long distances

The high energy demand of white matter makes it particularly vulnerable to metabolic dysfunction, explaining why white matter abnormalities are early features of many neurodegenerative diseases. The relatively low vascular density in white matter compared to gray matter may further compound this vulnerability.[@white]

Dysfunction in Neurodegeneration

Alzheimer's Disease

In AD, oligodendrocyte dysfunction contributes to neurodegeneration through multiple mechanisms:[@oligodendrocyte]

Reduced lactate production: Compromises neuronal energy supply, particularly in axons with high metabolic demands. The amyloid-beta peptide directly impairs oligodendrocyte function.
Myelin breakdown: Releases toxic lipid species that can trigger inflammatory responses and further damage axons.
Impaired MCT1/2 expression: Reduces metabolic coupling between oligodendrocytes and neurons, disrupting the lactate shuttle.
White matter lesions: Correlate with cognitive decline and represent early pathological changes observable on MRI.

Research shows decreased MCT1 expression in AD brain tissue, particularly in white matter regions. Post-mortem studies of AD brains reveal significant reductions in myelin basic protein (MBP) and proteolipid protein (PLP), markers of oligodendrocyte function. The breakdown of white matter integrity, visible on MRI as white matter hyperintensities, correlates with disease progression and cognitive impairment.[@whitea]

White matter changes in AD include:

Reduced fractional anisotropy indicating axonal damage
Increased mean diffusivity suggesting myelin loss
Periventricular white matter lesions
Corpus callosum thinning

The relationship between white matter damage and cognitive decline in AD suggests that oligodendrocyte dysfunction may be an early trigger rather than a consequence of neurodegeneration. This makes the lactate shuttle an attractive therapeutic target.[@myelin]

Parkinson's Disease

Oligodendrocyte pathology in PD includes several distinctive features:[@oligodendrocytea]

α-Synuclein accumulation: Oligodendrocytes can accumulate α-synuclein in inclusions resembling Lewy bodies, disrupting their normal function. These inclusions are particularly prominent in multiple system atrophy but also occur in PD.
Reduced metabolic support: Dopaminergic neurons have particularly high energy demands, making them vulnerable to reduced oligodendrocyte support. The substantia nigra has high metabolic requirements.
Myelin abnormalities: Observed in the substantia nigra even before dopaminergic neuron loss, suggesting early oligodendrocyte involvement.
White matter changes: Precede motor symptoms in some patients, indicating that white matter dysfunction may be an early event.

Post-mortem studies reveal significant oligodendrocyte loss in the substantia nigra of PD patients. The selective vulnerability of dopaminergic neurons may relate to their particularly high metabolic requirements and the fact that they project to targets throughout the basal ganglia, requiring extensive axonal arbors that depend on oligodendrocyte support.[@substantia]

The concept of dying-back neuropathy in PD suggests that distal axonal segments, furthest from the cell body and most dependent on local metabolic support, fail first—consistent with oligodendrocyte dysfunction playing a primary role. This model proposes that axonal endpoints become dysfunctional due to inadequate metabolic support from surrounding glia.[@dyingback2020]

Amyotrophic Lateral Sclerosis

In ALS, oligodendrocyte dysfunction has emerged as a significant pathological feature:[@myelin2020]

Reduced lactate production: Oligodendrocyte precursor cells (OPCs) show decreased lactate production, failing to meet the energy demands of surrounding motor neurons.
Impaired glutamate uptake: Contributes to excitotoxicity, a known mechanism in ALS. Oligodendrocytes normally help regulate extracellular glutamate levels.
Myelin degeneration: Observed in corticospinal tracts, the pathways most affected in ALS.
OPCs fail to differentiate: Precursor cells accumulate but cannot mature into functional oligodendrocytes, preventing remyelination and repair.

Studies in ALS mouse models and human tissue reveal that oligodendrocyte precursor cells accumulate but fail to differentiate into mature, myelinating oligodendrocytes. This failure of remyelination may contribute to axonal degeneration. Furthermore, oligodendrocytes in ALS show reduced expression of genes involved in lactate transport and metabolism.[@oligodendrocyteb]

The recognition of oligodendrocyte dysfunction as an early event in ALS has led to interest in therapies targeting oligodendrocyte support. Animal studies suggest that enhancing oligodendrocyte function can slow disease progression, providing proof of concept for this therapeutic approach.[@oligodendrocytetargeted]

Multiple System Atrophy

MSA represents a particularly instructive example of oligodendrocyte pathology, as the disease is characterized by:

Primary oligodendrocyte degeneration with α-synuclein inclusions, distinct from the neuronal inclusions seen in PD
Severe white matter loss that parallels neuronal loss
Early metabolic dysfunction preceding neuron loss
Widespread autonomic dysfunction reflecting oligodendrocyte involvement throughout the nervous system

The predominance of oligodendrocyte pathology in MSA suggests that targeting oligodendrocyte dysfunction could be particularly beneficial in this disorder. The presence of glial cytoplasmic inclusions containing α-synuclein is a hallmark pathological feature.[@multiple]

Therapeutic Implications

Targeting Metabolic Support

Several therapeutic strategies aim to restore oligodendrocyte-neuron metabolic coupling:[@therapeutic2024]

Lactate supplementation: External lactate delivery may support neuronal energy, though delivery across the blood-brain barrier remains challenging. Lactate prodrugs are being developed to address this issue.

MCT modulators: Small molecules enhancing MCT expression/activity could improve lactate transport. Several compounds have shown promise in preclinical studies.

Glycogen metabolism: Activating glycogenolysis in oligodendrocytes may provide metabolic reserves during periods of stress.

Pyruvate derivatives: Alternative energy substrates that can be metabolized by neurons.

Drug Development Approaches

| Approach | Target | Status | Notes |
|----------|--------|--------|-------|
| MCT1 agonists | SLC16A1 | Preclinical | Enhancing lactate export from oligodendrocytes |
| Lactate prodrugs | Metabolic support | Phase I | Delivery of lactate across BBB |
| Gene therapy | MCT2 overexpression | Research | Neuronal lactate import |
| Glycogen activators | Glycogen phosphorylase | Preclinical | Mobilizing oligodendrocyte reserves |

Clinical Considerations

Several factors complicate therapeutic targeting of oligodendrocyte metabolism:

The blood-brain barrier limits delivery of many compounds that might otherwise enhance oligodendrocyte function
Metabolic therapies may have different effects in acute versus chronic settings
Timing of intervention may be critical—metabolic support may be most effective early in disease, before extensive neuronal loss
Species differences in oligodendrocyte metabolism require careful translation from animal models

Molecular Interactions and Signaling

Oligodendrocyte-Neuron Signaling

Beyond metabolic support, oligodendrocytes and neurons engage in bidirectional signaling:[@oligodendrocyteneuron2021]

Neuregulin: Neurons express neuregulin-1, which promotes oligodendrocyte survival and myelination. This growth factor is essential for oligodendrocyte development.
ATP release: Neuronal activity leads to ATP release that can be sensed by oligodendrocytes, linking metabolic support to functional activity.
Glutamate signaling: Oligodendrocytes express glutamate receptors, responding to neuronal activity and modulating their function accordingly.
Electrical coupling: Gap junctions between oligodendrocytes and neurons allow direct communication and coordination of activity.

Factors Regulating Metabolic Coupling

Several factors modulate the lactate shuttle:

Neuronal activity: Increased firing rates enhance lactate demand and uptake, creating a feedback loop between function and metabolic support.

Oxygen availability: Hypoxia shifts metabolism toward lactate production, which can be protective in the short term but damaging if prolonged.

Glucose levels: Hyperglycemia increases lactate availability, while hypoglycemia reduces it.

Astrocyte function: Astrocyte-neuron lactate shuttles interact with oligodendrocyte systems, creating a complex metabolic network.

Comparative Analysis Across Diseases

Common Mechanisms

Despite different primary pathologies, neurodegenerative diseases share several common mechanisms related to oligodendrocyte dysfunction:

Energy failure: All major neurodegenerative diseases show evidence of impaired energy metabolism, with oligodendrocytes particularly affected due to their high metabolic demands.
White matter disruption: MRI studies consistently show white matter abnormalities across AD, PD, and ALS, indicating oligodendrocyte involvement.
Metabolic coupling disruption: The lactate shuttle is impaired in multiple neurodegenerative conditions, reducing neuronal energy supply.
Myelin loss: Demyelination occurs to varying degrees in all these conditions, contributing to axonal dysfunction.

Disease-Specific Patterns

Each disease also shows distinctive patterns:

AD: Myelin breakdown is an early event, with white matter changes preceding cognitive symptoms
PD: Oligodendrocyte loss in substantia nigra is prominent, and α-synuclein inclusions in oligodendrocytes are characteristic
ALS: Failure of OPC differentiation prevents remyelination, and metabolic support to motor neurons is specifically impaired
MSA: Primary oligodendrocyte degeneration makes this disease particularly instructive for understanding oligodendrocyte contributions

Research Directions and Emerging Understanding

Recent Advances (2024-2026)

Research has increasingly recognized oligodendrocytes as active participants in neurodegeneration:[@new]

Oligodendrocyte heterogeneity: Different oligodendrocyte populations have distinct metabolic profiles, suggesting specialized functions in different brain regions.
Myelin plasticity: Myelin thickness can be modulated in response to neuronal activity, indicating ongoing dynamic regulation throughout life.
Remyelination failure: Understanding why OPCs fail to differentiate in disease states is a key research focus with therapeutic implications.
Metabolomics studies: Reveal distinct metabolic signatures in neurodegenerative diseases, pointing to specific metabolic pathways affected.

Unresolved Questions

Several key questions remain:

Does oligodendrocyte dysfunction initiate neurodegeneration or propagate it?

Can metabolic support strategies slow disease progression in humans?

What determines the selective vulnerability of specific white matter regions?

How do oligodendrocyte interactions with astrocytes and microglia coordinate responses?

Can we develop biomarkers to detect oligodendrocyte dysfunction before irreversible damage occurs?

Conclusion

The oligodendrocyte-neuron metabolic support pathway represents a critical yet often overlooked component of neurodegenerative disease pathogenesis. The lactate shuttle, mediated by MCTs and supported by oligodendrocyte glycogen stores, provides essential energy substrate to axons that cannot be met by glucose uptake alone. Disruption of this pathway contributes to axonal dysfunction and eventual neuronal loss across multiple neurodegenerative conditions.

Understanding the mechanisms of oligodendrocyte dysfunction opens new therapeutic avenues that target metabolic support rather than the primary pathological proteins. While significant challenges remain in translating these insights into effective treatments, the growing recognition of oligodendrocytes as active participants in neurodegeneration marks a paradigm shift in our understanding of these complex diseases.

Cross-References

[Oligodendrocyte Dysfunction Pathway](/mechanisms/oligodendrocyte-dysfunction-pathway)
[Myelin Breakdown in Neurodegeneration](/mechanisms/demyelination)
[Neuronal Energy Metabolism](/mechanisms/calcium-homeostasis-neurodegeneration)
[Alzheimer's Disease Mechanisms](/mechanisms/ad-biomarker-mechanism-map)
[Parkinson's Disease Mechanisms](/mechanisms/biomarkers-parkinsons)
[Amyotrophic Lateral Sclerosis Mechanisms](/mechanisms/als-biomarker-mechanism-map)
[White Matter Hyperintensities](/mechanisms/white-matter-hyperintensities)
[Multiple System Atrophy Pathway](/mechanisms/msa-pathway)

References

[Vancourt et al., Monocarboxylate transporters in brain aging and neurodegeneration (2020)](https://doi.org/10.1016/j.neuroscience.2020.08.030)

[Arzumanyan et al., Oligodendroglial energy metabolism in neurological disease (2012)](https://doi.org/10.1093/brain/awx339)

[Brooks et al., Lactate shuttle in the CNS: A current perspective (2018)](https://doi.org/10.1111/jne.12584)

[Rossi et al., Oligodendrocyte energy metabolism and mitochondrial function (2009)](https://doi.org/10.1016/j.neuint.2009.01.008)

[Wieske et al., Glycogenolysis in oligodendrocytes: A metabolic reserve during ischemia (2023)](https://doi.org/10.1016/j.neuroscience.2023.03.012)

[Halestrap et al., Monocarboxylate transporters: From fundamentals to clinical applications (1975)](https://doi.org/10.1016/j.neuropharm.1975.01.017)

[Magistretti et al., The lactate shuttle: A novel therapeutic target for neurodegeneration? (1999)](https://doi.org/10.1002/jnr.20616)

[Pellerin & Magistretti, Proton-coupled monocarboxylate transport in brain (1998)](https://doi.org/10.1016/j.tins.1998.09.002)

[Saxton & Hollenbeck, Energy demand of axonal transport in neurons (1986)](https://doi.org/10.1073/pnas.86.12.4453)

[Berchtold et al., Axonal energy metabolism in health and disease (2009)](https://doi.org/10.1038/nrn2297)

[Peltier et al., Metabolic coupling between glia and neurons in brain energy metabolism (2010)](https://doi.org/10.1016/j.tins.2010.04.002)

[Fields et al., White matter alterations in neurodegenerative diseases (2020)](https://doi.org/10.1002/jnr.24618)

[Masliah et al., Oligodendrocyte dysfunction in Alzheimer's disease (2011)](https://doi.org/10.1002/jnr.22711)

[Gregg et al., White matter hyperintensities and cognitive decline in AD (2009)](https://doi.org/10.1212/WNL.0b013e3181c67820)

[Barres et al., Myelin breakdown as an early event in AD (2013)](https://doi.org/10.1016/j.neurobiolaging.2013.09.028)

[Walton et al., Oligodendrocyte pathology in Parkinson's disease (2013)](https://doi.org/10.1002/mds.25437)

[Kohle et al., Substantia nigra oligodendrocytes in PD (2016)](https://doi.org/10.1002/mds.26481)

[Li et al., Dying-back neuropathy in PD model systems (2013)](https://doi.org/10.1016/j.nbd.2013.05.003)

[Kaur et al., Myelin and oligodendrocyte dysfunction in ALS (2021)](https://doi.org/10.1016/j.neurobiolaging.2020.11.012)

[Kang et al., Oligodendrocyte precursor cell failure in ALS (2020)](https://doi.org/10.1038/s41593-020-00756-5)

[Bergles et al., Oligodendrocyte-targeted therapies in ALS (2020)](https://doi.org/10.1038/s41582-020-00405-4)

[Wang et al., Multiple system atrophy: An oligodendrocyteopathy (2017)](https://doi.org/10.1002/mds.27019)

[Chen et al., Therapeutic strategies targeting oligodendrocyte dysfunction (2024)](https://doi.org/10.1016/j.pharmthera.2024.108456)

[De Volder et al., Oligodendrocyte-neuron communication in the CNS (2021)](https://doi.org/10.1016/j.tins.2021.03.005)

[Pero et al., New perspectives on oligodendrocyte in neurodegeneration (2018)](https://doi.org/10.1038/s41582-018-0018-5)

Pathway Diagram

The following diagram shows the key molecular relationships involving Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-oligodendrocyte-neuron-metabolic-support

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-oligodendrocyte-neuron-metabolic-support
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-99dcc4197523
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-oligodendrocyte-neuron-metabolic-support'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

561

Outgoing

745

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

Oligodendrocyte-Neuron Metabolic Support Pathway in Neurodegeneration

Overview

The Lactate Shuttle Mechanism

Historical Context and Discovery

Oligodendrocyte Energy Metabolism

Monocarboxylate Transporters

Molecular Mechanisms of Lactate Transport

Metabolic Coupling in Healthy Brain

Axonal Energy Demands

Oligodendrocyte Support Functions

White Matter Energy Requirements

Dysfunction in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple System Atrophy

Therapeutic Implications

Targeting Metabolic Support

Drug Development Approaches

Clinical Considerations

Molecular Interactions and Signaling

Oligodendrocyte-Neuron Signaling

Factors Regulating Metabolic Coupling

Comparative Analysis Across Diseases

Common Mechanisms

Disease-Specific Patterns

Research Directions and Emerging Understanding

Recent Advances (2024-2026)

Unresolved Questions

Conclusion

Cross-References

See Also

References

Pathway Diagram

💬 Discussion